CHR-6494 TFA

Research use only, not for human use.

CHR-6494 TFA is a potent haspin inhibitor, with an?IC50?of 2 nM. It inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the?apoptosis?of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer.

CHR-6494 TFA is a potent haspin inhibitor, with an?IC50?of 2 nM. It inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the?apoptosis?of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer.(In Vitro):Administration of CHR-6494 (TFA; 0-10-5?nM; 72 hours) dose-dependently inhibits the growth of cancer cells, such as HCT-116, HeLa, MDA-MB-231, and Wi-38 cells, with an IC50s of 500?nM, 473?nM, 752?nM and 1059 nM, respectively. Administration of CHR-6494 (TFA; 500 nM) produces a mitotic catastrophe with abnormal morphology of the mitotic spindle and centrosome amplification, and upregulates the spindle assembly checkpoint protein BUB1 and the marker of mitotic arrest cyclin B1.(In Vivo):Administration of CHR-6494 (TFA; 50?mg/kg; i.p. in two cycles of five consecutive days for 15 days) inhibits the growth of tumor and no obvious body weight change is observed in nude mice bearing HCT-116 human colorectal cancer cells.

CHR 6494 TFA

Others

Other Targets

DHODH

——

——

1458630-17-5

406.4

C18H17F3N6O2

>98% (HPLC)

——

OC(=O)C(F)(F)F.CCCNc1ccc2ncc(-c3ccc4[nH]ncc4c3)n2n1

——

(-20℃)

With Ice Pack

≥ 2 years